Yuko Ishii

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 2 papers. Top paper: “Efficacy and Safety of Nivolumab Plus Ipilimumab versus Sunitinib in First-line Treatment of Patients with Advanced Sarcomatoid Renal Cell Carcinoma”.

Efficacy and Safety of Nivolumab Plus Ipilimumab versus Sunitinib in First-line Treatment of Patients with Advanced Sarcomatoid Renal Cell Carcinoma

Clinical Cancer Research(2020)10.1158/1078-0432.ccr-20-2063

N/A

0DataRank · unranked

243 citations

Sabina Signoretti, Toni K. Choueiri, David F. McDermott, Robert J. Motzer, Abdallah Flaifel +19 more

Data from Efficacy and Safety of Nivolumab Plus Ipilimumab versus Sunitinib in First-line Treatment of Patients with Advanced Sarcomatoid Renal Cell Carcinoma

(2023)10.1158/1078-0432.c.6529871

N/A

0DataRank · unranked

0 citations

Sabina Signoretti, Toni K. Choueiri, David F. McDermott, Robert J. Motzer, Abdallah Flaifel +19 more